Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: Efficacy, tolerance, and treatment approach

Keyphrases

• Bloody Diarrhea 25%
• Budesonide 100%
• Budesonide Foam 25%
• Colon 25%
• Cost Profile 25%
• Distal Colitis 100%
• Distal Colon 25%
• Efficacy Profile 25%
• Enema 100%
• Foam Formulation 25%
• Immune-mediated Diseases 25%
• Immunosuppressive Therapy 25%
• Inflammation 50%
• Mesalamine 100%
• Mild-to-moderate Ulcerative Colitis 25%
• Moderate to Severe 50%
• Mucosal Inflammation 25%
• Patient Education 25%
• Patient Tolerance 50%
• Patient-physician 25%
• Placebo 25%
• Proctitis 25%
• Proctosigmoiditis 100%
• Rectal Suppositories 25%
• Rectum 25%
• Remission 50%
• Remission Rate 25%
• Safety Profile 25%
• Safety Self-efficacy 25%
• Side Effect Profile 50%
• Splenic Flexure 25%
• Tolerability 25%
• Tolerance Approach 100%
• Topical Formulation 25%
• Topical Treatment 25%
• Treatment Strategy 100%
• Ulcerative Colitis 25%
• Ulcerative Colitis Patient 25%
• Underuse 25%

Medicine and Dentistry

• Bloody Diarrhea 16%
• Budesonide 100%
• Colitis 16%
• Colon 33%
• Diseases 16%
• Enema 66%
• Health Care Cost 33%
• Immunity 16%
• Immunosuppressive Treatment 16%
• Mesalazine 100%
• Placebo 16%
• Proctitis 16%
• Rectal Administration 16%
• Side Effect 33%
• Splenic Flexure 16%
• Spontaneous Remission 16%
• Topical Treatment 16%
• Ulcerative Colitis 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Aminosalicylic Acid 100%
• Bloody Diarrhea 16%
• Budesonide 100%
• Colitis 16%
• Diseases 16%
• Enema 66%
• Immunosuppressive Agent 16%
• Inflammation 50%
• Placebo 16%
• Proctitis 16%
• Rectal Administration 16%
• Remission 50%
• Side Effect 33%
• Tolerability 16%
• Ulcerative Colitis 100%